Cellular immunotherapies show promising clinical results for the treatment of cancers, notably with chimeric antigen receptor (CAR) technology, which commonly relies on autologous T cells engineered to heterologously express a synthetic CAR construct enabling T cell anticancer responses targeted towards cancer-associated antigens (e.g. CD19), upon patient re-infusion2,3. Here, CD19 is linked to cancer.